MPE Masterclass 2024 | Agenda

14:00 – 17:00 Participants check-in and registration
19:00 – 22:00 Welcome dinner at the hotel restaurant
09:00 – 09:15

Welcome

Lise-lott Eriksson, President of MPE

 
09:15 – 10:30

Plenary session 1 –  Myeloma and AL amyloidosis treatment updates

Dr Albert Oriol, Head of the Clinical Research Unit, Institut Català d’Oncologia (ICO)

 
10:35 – 11:35

Plenary session 2 – Side effects and management of myeloma and AL amyloidosis treatment

Dr Charlotte Pawlyn, Haematologist and Clinician Scientist, Cancer Research UK

 
11:35 – 12.00Coffee break  
12:00 – 13:15

Plenary session 3 – Real World Evidence (RWE)

  • Karen Facey, PhD CStat Hon MFPH, FIPRA Public Affairs, Senior Advisor – Health Technology Assessment
  • Dr Jelena Bila, Professor Dr sci med, Head of the Ward at Clinic of Hematology, University Clinical Center of Serbia
  • Martine Elias, Executive Director, Myeloma Canada
 
13:15 – 14:30Morning session close and lunch break 
14:30 – 15:30

Breakout session 1 – Shared decision-making: improving effective communication between the patient and the medical team

  • Silene Ten Seldam, Research Assistant, MPE

Breakout session 2 – Addressing challenges and importance of the European Young Myeloma Patients Group

  • Ellen Watters, Myeloma Information Specialist, Myeloma UK
  • Vincent Claus, Myeloma Patient and Leader of European Young Myeloma Patients Group, Belgium
15:30 – 16:00Coffee break
 
16:00 – 17:00

Plenary Session 4 – Cross-border access to medicine and trials

  • Ananda Plate, Executive Director, Patvocates
  • Expert from EPF, TBD
17:00 – 18:00Poster presentations and info stands
(15 mins poster introduction and 45 mins presentation)
Member programmes, success stories and MPE projects
20:00 – 23:00Offsite dinner
09:00 – 09:15 Welcome
09:15 – 10:30 Plenary Session 5 – EU Health Technology Assessment Regulation
  • Valentina Strammiello, Director of Programmes, EPF project portfolio and represents EPF in HTA-related activities in the European Health Parliament initiative
  • Karen Facey, PhD CStat Hon MFPH, FIPRA Public Affairs, Senior Advisor – Health Technology Assessment
10:30 – 11:00 Coffee break 
11:00 – 11:30 Video screening – “Myeloma is our story”
11:30 – 12:45 Panel Discussion 1 – Supportive care for myeloma and AL amyloidosis patients
  • Surabhi Chaturvedi, Senior psychotherapist and team lead (Haemato-Oncology/ Transplant/ CAR-T) at King’s College Hospital NHS Foundation Trust
  • Orla McCourt, Clinical academic physiotherapist at University College London Hospitals NHS Foundation Trust (UCLH)
  • Nada Rotovnik Kozjek, PhD, MD, Head, Clinical Nutrition Unit, Institute of Oncology Ljubljana, Slovenia
  • Christine Skeet, Nurse Specialist, Eastbourne, England, United Kingdom
12:45 – 12:55 Clinical Trial Navigator launch Solène Clavreul, PhD, Head of Medical Education and Scientific Engagement, MPE
12:55 – 13:00 Masterclass close
12:55 – 13:00 Farewell lunch